https://www.selleckchem.com/pr....oducts/pixantrone-ma
Its expression levels were markedly lower in relapse patients than in controls ( -value of 0.058). In a second phase, this finding could be validated in an independent set of 53 patients using ddPCR. Patients with enhanced levels of hsa-miR-375 compared to RASD1 had a higher probability of local relapse than those with the inverse expression pattern of the two markers (log-rank test, -value = 0.069). This two-phase study demonstrates that hsa-miR-375/RASD1 signaling is able to predict local control in early breast cancer pati
Aimer
Commentaire
Partagez
